Accera discovers and develops breakthrough therapies for central nervous system (CNS) disorders with the goal of improving quality of life for patients and their families. We focus on serious and difficult-to-diagnose neurodegenerative diseases for which there are no simple therapies. Accera is pioneering innovative scientific approaches to treating CNS disorders with unique products that target the underlying factors that give rise to disease symptoms.
Through our proprietary scientific platform, Accera is developing therapies that address metabolic deficiencies and provide alternative energy sources for brain cells. Our first product, Axona®, is a prescription medical food intended for the clinical dietary management of the metabolic processes associated with mild to moderate Alzheimer's disease.
Accera recognizes that patients with CNS disorders need effective, well-tolerated therapies, and we hope that our novel therapeutic approaches positively impact these patients and their families. We are committed to improving the care and quality of life of patients.